【摘要】 目的探讨甘露糖化肿瘤疫苗在抗肿瘤免疫中的作用。方法纯化出目的蛋白HER-2/neu胞外配体第2结构域(RLD2),并对其进行糖基化修饰,自外周血单核细胞诱导产生CD83+的DC,利用DC表面的甘露糖受体,使DC负载甘露糖基化的目的抗原mRLD2(mL2),并致敏T淋巴细胞,观察CTL特异性杀伤SKBR-3细胞的效果。结果较之未进行糖基化修饰的目的蛋白RLD2(L2),mL2能促进DC的成熟,并能诱导出具有更强杀伤效力的CTL。结论本实验的结果为开展新型甘露糖化肿瘤疫苗的研制提供了理论依据。更多还原

【Abstract】 AIM: To investigate the role of mannosylated tumor antigen in the course of anti-tumor response. METHODS: L2 domain of HER-2/neu (ErbB2) ectodomain was expressed in E.coli, purified and mannosylated. Dendritic cells(DCs) were induced from human peripheral blood mononuclear cell by GM-CSF and IL-4. The maturation and functional capacity of DCs pulsed with mannosylated L2 (mL2) protein was investigated. RESULTS: L2 protein could induce DC maturation, which was accompanied by elevated expression of MHC and costimulatory molecules. The effect of mL2 protein on DC maturation was more remarkable than that of non-mannosylated L2 protein. Furthermore, DCs pulsed with mL2 could stimulate high tumor cell lysis by CTL. CONCLUSION: Our experiment provide the foundation for the study of new tumor vaccine by mannosylation.更多还原